The effect of biocompatible peritoneal dialysis solutions on neutrophil to lymphocyte ratio

References

• Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927–1939
   PubMed Web of Science ®Google Scholar
• Catalan MP, Santamarıa B, Reyero A, Ortiz A, Egido J, Ortiz A. 3,4-Di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int. 2005;68:1303–1311
   PubMedGoogle Scholar
• Mortier S, De Vriese AS, McLoughlin RM, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol. 2003;14:1296–1306
   PubMed Web of Science ®Google Scholar
• Stankovic-Popovic V, Nesic V, Popovic D, et al. Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients. Clin Nephrol. 2011;76:314–322
   Google Scholar
• Furkert J, Zeier M, Schwenger V. Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int. 2008;28:637–640
   PubMedGoogle Scholar
• Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int. 2005;25:248–255
   PubMed Web of Science ®Google Scholar
• Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. AmJ Kidney Dis. 2009;54:711–720
   PubMed Web of Science ®Google Scholar
• Lee HY, Choi HY, Park HC, et al. Changing prescribing practice in CAPD patients in Korea: Increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant. 2006;21:2893–2899
   Google Scholar
• Johnson DW, Brown FG, Clarke M, et al.; balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012;23:1097–1107
   Google Scholar
• Tranaeus A; The Bicarbonate/Lactate Study Group. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution – clinical benefits. Perit Dial Int. 2000;20:516–523
   Google Scholar
• Coles GA, O’Donoghue DJ, Pritchard N, et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD – final report. Nephrol Dial Transplant. 1998;13:3165–3171
   Google Scholar
• Fernandez-Perpen A, Perez-Lozano ML, Bajo MA, et al. Influence of bicarbonate/Low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells. Perit Dial Int. 2012;32:292–304
   Google Scholar
• Haag-Weber M, Kramer R, Haake R, et al.; behalf of the DIUREST Study Group. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: A prospective randomized study. Nephrol Dial Transplant. 2010;25:2288–2296
   PubMed Web of Science ®Google Scholar
• Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012;34:155–159
   PubMed Web of Science ®Google Scholar
• Okyay GU, Inal S, Oneç K, et al. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail. 2013;35:29–36
   PubMed Web of Science ®Google Scholar
• An X, Mao HP, Wei X, et al. Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. Int Urol Nephrol. 2012;44:1521–1528
   PubMed Web of Science ®Google Scholar
• Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2013 [Epub ahead of print]. doi: 10.3109/15569527.2013.834498
   Google Scholar
• Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5:2 . doi: 10.1186/1755-7682-5-2
   PubMedGoogle Scholar
• Li PK, Szeto CC, Piraino B, et al.; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JCK. Inflammation in peritoneal dialysis. Nephron Clin Pract. 2010;116:11–18
   PubMedGoogle Scholar
• Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11:498–506
   PubMed Web of Science ®Google Scholar
• Topley N. Membrane longevity in peritoneal dialysis: Impact of infection and bioincompatible solutions. Adv Ren Replace Ther. 1998;5:179–184
   PubMedGoogle Scholar
• Chen CH, Cheng CH, Wu MJ, et al. A comparison of biocompatible balance solution and standard peritoneal dialysis solution in a single center of central Taiwan: A pilot study. Acta Nephrologica. 2012;26:8–14
   Google Scholar
• Maksic D, Vasilijic S, Colic M, Stankovic-Popovic V, Bokonjic D. Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2009;25:50–55
   PubMedGoogle Scholar
• Johnson DW, Brown FG, Clarke M, et al.; balANZ Trial Investigators. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: The balANZ trial. Perit Dial Int. 2012;32:497–506
   Google Scholar
• Cho Y, Badve SV, Hawley CM, et al. Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes. Clin J Am Soc Nephrol. 2013;8:1556–1563
   Google Scholar
• Schwan WR, Lee JL, Lenard FA, Matthews BT, Beck MT. Osmolarity and pH growth conditions regulate fim gene transcription and type 1 pilus expression in uropathogenic Escherichia coli. Infect Immun. 2002;70:1391–1402
   Google Scholar
• Gonzales L, Ali ZB, Nygren E, et al. Alkaline pH Is a signal for optimal production and secretion of the heat labile toxin, LT in enterotoxigenic Escherichia coli (ETEC). PLoS One. 2013;8:e74069
   Google Scholar
• Nostro A, Cellini L, Ginestra G, et al. Staphylococcal biofilm formation as affected by type acidulant. APMIS. 2013;122:648--653
   Google Scholar